Supplemental Vitamins and Minerals for CVD Prevention and Treatment

Journal of the American College of Cardiology

Volumn 71, Issue 22, 2018, Pages 2570-2584

  Jenkins, David J A ^a,b,c   Spence, J David ^d   Giovannucci, Edward L ^e   Kim, Young in ^a,c,f   Josse, Robert ^a,b,c   Vieth, Reinhold ^a   Blanco Mejia, Sonia ^a,c   Viguiliouk, Effie ^a,c   Nishi, Stephanie ^a,c   Sahye Pudaruth, Sandhya ^a,c   Paquette, Melanie ^a,c   Patel, Darshna ^a,c   Mitchell, Sandy ^a,c   Kavanagh, Meaghan ^a,c   Tsirakis, Tom ^c   Bachiri, Lina ^g   Maran, Atherai ^c   Umatheva, Narmada ^c   McKay, Taylor ^c   Trinidad, Gelaine ^c   Bernstein, Daniel ^c   Chowdhury, Awad ^c   Correa Betanzo, Julieta ^c   Del Principe, Gabriella ^c   Hajizadeh, Anisa ^c   Jayaraman, Rohit ^c   Jenkins, Amy ^c   Jenkins, Wendy ^c   Kalaichandran, Ruben ^c   Kirupaharan, Geithayini ^c   Manisekaran, Preveena ^c   Qutta, Tina ^c   Shahid, Ramsha ^c   Silver, Alexis ^c   Villegas, Cleo ^c   White, Jessica ^c   Kendall, Cyril W C ^a,c,h   Pichika, Sathish C ^a,c,i   Sievenpiper, John L ^a,b,c   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g AGROPARISTECH   (France)

^h UNIVERSITY OF SASKATCHEWAN   (Canada)

ⁱ UNIVERSITY OF WINDSOR   (Canada)

Author keywords

all cause mortality; meta analysis; supplements

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CALCIUM; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINERAL; MULTIVITAMIN; NICOTINIC ACID; SELENIUM; VITAMIN; VITAMIN B COMPLEX; VITAMIN B GROUP; VITAMIN D; TRACE ELEMENT;

ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; HEART INFARCTION; HEART PROTECTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; UNITED STATES; VITAMIN SUPPLEMENTATION; DIET THERAPY; DIETARY SUPPLEMENT; HEALTHY DIET; PROCEDURES; TREATMENT OUTCOME; TRENDS;

CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; HEALTHY DIET; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRACE ELEMENTS; TREATMENT OUTCOME; VITAMINS;

EID: 85047259193     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.04.020     Document Type: Review

References (94)

1. Baron, J.H., Sailors' scurvy before and after James Lind–a reassessment. Nutr Rev 67 (2009), 315–332.
2. Kantor, E.D., Rehm, C.D., Du, M., White, E., Giovannucci, E.L., Trends in dietary supplement use among US adults from 1999–2012. JAMA 316 (2016), 1464–1474.
3. Skeie, G., Braaten, T., Hjartåker, A., et al. Use of dietary supplements in the European Prospective Investigation into Cancer and Nutrition calibration study. Eur J Clin Nutr 63 Suppl 4 (2009), S226–S238.
4. Canadian Cancer Society. Nutrition and Fitness (Healthy Eating, Vitamin D). 2018. Available at: http://www.cancer.ca/en/prevention-and-screening/reduce-cancer-risk/make-healthy-choices/eat-well/should-i-take-a-vitamin-d-supplement/?region=on. Accessed April 20, 2018.
5. Office of Disease Prevention and Health Promotion. Advisory Report. Report Index Available at: https://health.gov/dietaryguidelines/2015-scientific-report. Accessed April 17, 2018.
6. Fortmann, S.P., Burda, B.U., Senger, C.A., Lin, J.S., Whitlock, E.P., Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 159 (2013), 824–834.
7. Moyer, V.A., U.S. Preventive Services Task Force. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive services Task Force recommendation statement. Ann Intern Med 160 (2014), 558–564.
8. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2008. Available at: http://handbook-5-1.cochrane.org. Accessed April 17, 2018.
9. Higgins, J.P.T., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
10. Centre for Evidence-Based Medicine. Number needed to treat (NNT). Definition. Available at: https://www.cebm.net/2014/03/number-needed-to-treat-nnt. Accessed April 17, 2018.
11. Higgins, J.P.T., Altman, D.G., Gøtzsche, P.C., et al., Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
12. Guyatt, G., Oxman, A.D., Akl, E.A., et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64 (2011), 383–394.
13. Guyatt, G.H., Oxman, A.D., Kunz, R., et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64 (2011), 395–400.
14. Balshem, H., Helfand, M., Schünemann, H.J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64 (2011), 401–406.
15. Guyatt, G.H., Oxman, A.D., Vist, G., et al. GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). J Clin Epidemiol 64 (2011), 407–415.
16. Guyatt, G.H., Oxman, A.D., Montori, V., et al. GRADE guidelines: 5. Rating the quality of evidence–publication bias. J Clin Epidemiol 64 (2011), 1277–1282.
17. Guyatt, G.H., Oxman, A.D., Kunz, R., et al. GRADE guidelines 6. Rating the quality of evidence–imprecision. J Clin Epidemiol 64 (2011), 1283–1293.
18. Guyatt, G.H., Oxman, A.D., Kunz, R., et al., GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence–inconsistency. J Clin Epidemiol 64 (2011), 1294–1302.
19. Guyatt, G.H., Oxman, A.D., Kunz, R., et al., GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence–indirectness. J Clin Epidemiol 64 (2011), 1303–1310.
20. Guyatt, G.H., Oxman, A.D., Sultan, S., et al., GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 64 (2011), 1311–1316.
21. Brunetti, M., Shemilt, I., Pregno, S., et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 66 (2013), 140–150.
22. Guyatt, G., Oxman, A.D., Sultan, S., et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 66 (2013), 151–157.
23. Guyatt, G.H., Oxman, A.D., Santesso, N., et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 66 (2013), 158–172.
24. Guyatt, G.H., Thorlund, K., Oxman, A.D., et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 66 (2013), 173–183.
25. Bender, R., Lange, S., Multiple test procedures other than Bonferroni's deserve wider use. BMJ 318 (1999), 600–601.
26. CONSORT Website. The Consort Statement. Available at: www.CONSORT-statement.org. Accessed April 17, 2018.
27. Liem, A., Reynierse-Buitenwerf, G.H., Zwinderman, A.H., Jukema, J.W., van Veldhuisen, D.J., Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 41 (2003), 2105–2113.
28. Liem, A.H., van Boven, A.J., Veeger, N.J., et al., FOLic Acid on Risk Diminishment after Acute myocardial infarction (FOLARDA) study group. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol 93 (2004), 175–179.
29. Zoungas, S., McGrath, B.P., Branley, P., et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 47 (2006), 1108–1116.
30. Cole, B.F., Baron, J.A., Sandler, R.S., et al., Polyp Prevention Study Group. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297 (2007), 2351–2359.
31. Logan, R.F., Grainge, M.J., Shepherd, V.C., Armitage, N.C., Muir, K.R., ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134 (2008), 29–38.
32. Wu, K., Platz, E.A., Willett, W.C., et al. A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr 90 (2009), 1623–1631.
33. Huo, Y., Li, J., Qin, X., et al., CSPPT Investigators. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 313 (2015), 1325–1335.
34. Righetti, M., Ferrario, G.M., Milani, S., et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 9 (2003), PI19–PI24.
35. Vianna, A.C., Mocelin, A.J., Matsuo, T., et al. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 11 (2007), 210–216.
36. Bønaa, K.H., Njølstad, I., Ueland, P.M., et al., NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006), 1578–1588.
37. Jamison, R.L., Hartigan, P., Kaufman, J.S., et al., Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298 (2007), 1163–1170.
38. Ebbing, M., Bleie, Ø., Ueland, P.M., et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 300 (2008), 795–804.
39. Albert, C.M., Cook, N.R., Gaziano, J.M., et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299 (2008), 2027–2036.
40. Saposnik, G., Ray, J.G., Sheridan, P., McQueen, M., Lonn, E., Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 40 (2009), 1365–1372.
41. Imasa, M.S., Gomez, N.T., Nevado, J.B. Jr., Folic acid-based intervention in non-ST elevation acute coronary syndromes. Asian Cardiovasc Thorac Ann 17 (2009), 13–21.
42. VITATOPS Trial Study Group, B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 9 (2010), 855–865.
43. Heinz, J., Kropf, S., Domröse, U., et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 121 (2010), 1432–1438.
44. Galan, P., Kesse-Guyot, E., Czernichow, S., Briancon, S., Blacher, J., Hercberg, S., SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ, 341, 2010, c6273.
45. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 303 (2010), 2486–2494.
46. House, A.A., Eliasziw, M., Cattran, D.C., et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303 (2010), 1603–1609.
47. van Dijk, S.C., Enneman, A.W., Swart, K.M., et al. Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial. J Hypertens 33 (2015), 1897–1906 discussion 1906.
48. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975), 360–381.
49. Sang, Z.C., Wang, F., Zhou, Q., et al. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Chinese Med J (Engl) 122 (2009), 1615–1620.
50. AIM-HIGH Investigators, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
51. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
52. McKeown-Eyssen, G., Holloway, C., Jazmaji, V., Bright-See, E., Dion, P., Bruce, W.R., A randomized trial of vitamins C and E in the prevention of recurrence of colorectal polyps. Cancer Res 48 (1988), 4701–4705.
53. Omenn, G.S., Goodman, G.E., Thornquist, M.D., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 (1996), 1150–1155.
54. Girodon, F., Lombard, M., Galan, P., et al. Effect of micronutrient supplementation on infection in institutionalized elderly subjects: a controlled trial. Ann Nutr Metab 41 (1997), 98–107.
55. Girodon, F., Galan, P., Monget, A.L., et al., MIN. VIT. AOX. geriatric network. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. Arch Intern Med 159 (1999), 748–754.
56. Salonen, J.T., Nyyssönen, K., Salonen, R., et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 248 (2000), 377–386.
57. Correa, P., Fontham, E.T., Bravo, J.C., et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 92 (2000), 1881–1888.
58. Jacobson, J.S., Begg, M.D., Wang, L.W., et al. Effects of a 6-month vitamin intervention on DNA damage in heavy smokers. Cancer Epidemiol Biomarkers Prev 9 (2000), 1303–1311.
59. Brown, B.G., Zhao, X.Q., Chait, A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001), 1583–1592.
60. Age-Related Eye Disease Study Research Group, A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 119 (2001), 1439–1452 erratum Arch Ophthalmol 2008;126:1251.
61. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 23–33.
62. Waters, D.D., Alderman, E.L., Hsia, J., et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288 (2002), 2432–2440.
63. Chylack, L.T. Jr., Brown, N.P., Bron, A., et al. The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Ophthalmic Epidemiol 9 (2002), 49–80.
64. Virtamo, J., Pietinen, P., Huttunen, J.K., et al., ATBC Study Group. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 290 (2003), 476–485.
65. Mooney, L.A., Madsen, A.M., Tang, D., et al. Antioxidant vitamin supplementation reduces benzo(a)pyrene-DNA adducts and potential cancer risk in female smokers. Cancer Epidemiol Biomarkers Prevention 14 (2005), 237–242.
66. Critical Leg Ischaemia Prevention Study (CLIPS) Group, Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 261 (2007), 276–284.
67. Plummer, M., Vivas, J., Lopez, G., et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst 99 (2007), 137–146.
68. Cook, N.R., Albert, C.M., Gaziano, J.M., et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 167 (2007), 1610–1618.
69. Lippman, S.M., Klein, E.A., Goodman, P.J., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301 (2009), 39–51.
70. Hercberg, S., Kesse-Guyot, E., Druesne-Pecollo, N., et al. Incidence of cancers, ischemic cardiovascular diseases and mortality during 5-year follow-up after stopping antioxidant vitamins and minerals supplements: a postintervention follow-up in the SU.VI.MAX Study. Int J Cancer 127 (2010), 1875–1881.
71. Ma, J.L., Zhang, L., Brown, L.M., et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 104 (2012), 488–492.
72. Wang, L., Sesso, H.D., Glynn, R.J., et al. Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians' Health Study II randomized trial. Am J Clin Nutr 100 (2014), 915–923.
73. Collin, S.M., Metcalfe, C., Refsum, H., et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 19 (2010), 1632–1642.
74. Stolzenberg-Solomon, R.Z., Chang, S.C., Leitzmann, M.F., et al. Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr 83 (2006), 895–904.
75. Lawson, K.A., Wright, M.E., Subar, A., et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99 (2007), 754–764.
76. Chou, R., Dana, T., Blazina, I., et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Statin Use for the Prevention of Cardiovascular Disease in Adults: A Systematic Review for the US Preventive Services Task Force. Evidence Synthesis No. 139. AHRQ Publication No. 14-05206-EF-2. 2016, Agency for Healthcare Research and Quality, Rockville, MD.
77. Zhang, C., Wang, Z.Y., Qin, Y.Y., Yu, F.F., Zhou, Y.H., Association between B vitamins supplementation and risk of cardiovascular outcomes: a cumulative meta-analysis of randomized controlled trials. PloS One, 9, 2014, e107060.
78. Dong, H., Pi, F., Ding, Z., et al. Efficacy of supplementation with B vitamins for stroke prevention: a network meta-analysis of randomized controlled trials. PloS One, 10, 2015, e0137533.
79. Klein, E.A., Thompson, I.M. Jr., Tangen, C.M., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306 (2011), 1549–1556.
80. Spence, J.D., Metabolic vitamin B12 deficiency: a missed opportunity to prevent dementia and stroke. Nutr Res 36 (2016), 109–116.
81. Spence, J.D., Stampfer, M.J., Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA 306 (2011), 2610–2611.
82. Spence, J.D., Urquhart, B.L., Bang, H., Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine. Nephrol Dial Transplant 31 (2016), 937–944.
83. Forouhi, N.G., Luan, J., Cooper, A., Boucher, B.J., Wareham, N.J., Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes 57 (2008), 2619–2625.
84. Mattila, C., Knekt, P., Männistö, S., et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 30 (2007), 2569–2570.
85. Zheng, W., Anderson, K.E., Kushi, L.H., et al. A prospective cohort study of intake of calcium, vitamin D, and other micronutrients in relation to incidence of rectal cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 7 (1998), 221–225.
86. Park, Y., Leitzmann, M.F., Subar, A.F., Hollenbeck, A., Schatzkin, A., Dairy food, calcium, and risk of cancer in the NIH-AARP Diet and Health Study. Arch Intern Med 169 (2009), 391–401.
87. Baron, J.A., Beach, M., Mandel, J.S., et al., Calcium Polyp Prevention Study Group. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 340 (1999), 101–107.
88. Bonithon-Kopp, C., Kronborg, O., Giacosa, A., Räth, U., Faivre, J., European Cancer Prevention Organisation Study Group. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. Lancet 356 (2000), 1300–1306.
89. Willett, W.C., Take a multivitamin for insurance. Willit, W.C., Skerrit, P.J., (eds.) Eat, Drink, and Be Healthy: the Harvard Medical School Guide to Healthy Eating, 2001, Simon & Schuster Source, New York, 205–236.
90. Leung Yinko, S.S., Pelletier, R., Behlouli, H., et al., GENESIS-PRAXY Investigators. Potential factors associated with fruit and vegetable intake after premature acute coronary syndrome: a prospective cohort study. Int J Food Sci Nutr 66 (2015), 943–949.
91. Peto, R., Awasthi, S., Read, S., Clark, S., Bundy, D., Vitamin A supplementation in Indian children - Authors' reply. Lancet 382 (2013), 594–596.
92. Anderson, T.J., Boden, W.E., Desvigne-Nickens, P., et al., AIM-HIGH Investigators. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med 371 (2014), 288–290.
93. Health Canada, Summary of Guiding Principles and Recommendations. 2017. Available at: https://www.foodguideconsultation.ca/guiding-principles-summary Accessed April 17, 2018.
94. Keene, D., Price, C., Shun-Shin, M.J., Francis, D.P., Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ, 349, 2014, g4379.